Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![whispertickers Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1937935302200373248.png) WhisperTick [@whispertickers](/creator/twitter/whispertickers) on x XXX followers
Created: 2025-07-17 18:27:33 UTC

The cannabis sector in 2025 is a tale of two markets. While US operators like Curaleaf $CURLF and Green Thumb $GTBIF thrive, Canadian firms such as Canopy Growth $CGC face perilous declines. 

• Curaleaf and Green Thumb benefit from vertical integration and consistent US market growth, yet face regulatory uncertainties. 
• Canopy struggles with an oversaturated market and persistent financial losses. Their shares have dropped nearly XX% since January.
• Tilray's $TLRY diversification into non-cannabis sectors offers a buffer but leaves core business consistency in question.

The potential US rescheduling of cannabis to Schedule III lurks as a catalyst—and a conundrum. Execution, not just hype, will separate winners from laggards. Discover more insights and what's next in our detailed analysis:

![](https://pbs.twimg.com/media/GwFF0GTXQAE--_y.png)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945913278695133614/c:line.svg)

**Related Topics**
[$cgc](/topic/$cgc)
[$weedto](/topic/$weedto)
[$gtbif](/topic/$gtbif)
[$curlf](/topic/$curlf)

[Post Link](https://x.com/whispertickers/status/1945913278695133614)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

whispertickers Avatar WhisperTick @whispertickers on x XXX followers Created: 2025-07-17 18:27:33 UTC

The cannabis sector in 2025 is a tale of two markets. While US operators like Curaleaf $CURLF and Green Thumb $GTBIF thrive, Canadian firms such as Canopy Growth $CGC face perilous declines.

• Curaleaf and Green Thumb benefit from vertical integration and consistent US market growth, yet face regulatory uncertainties. • Canopy struggles with an oversaturated market and persistent financial losses. Their shares have dropped nearly XX% since January. • Tilray's $TLRY diversification into non-cannabis sectors offers a buffer but leaves core business consistency in question.

The potential US rescheduling of cannabis to Schedule III lurks as a catalyst—and a conundrum. Execution, not just hype, will separate winners from laggards. Discover more insights and what's next in our detailed analysis:

XXX engagements

Engagements Line Chart

Related Topics $cgc $weedto $gtbif $curlf

Post Link

post/tweet::1945913278695133614
/post/tweet::1945913278695133614